Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136885> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4324136885 endingPage "695" @default.
- W4324136885 startingPage "695" @default.
- W4324136885 abstract "695 Background: Recent results from COSMIC 313 trial and updated findings from other contemporary trials have added to the existing body of evidence for 1L mRCC. Therefore, we present the most up-to-date results from our living, interactive systematic review (LISR) to facilitate the choice of optimal therapy in 1L mRCC setting. Methods: This LISR and network meta-analysis is maintained using a novel living evidence synthesis (LIvE) framework. The framework facilitates the identification of new or updated studies using an automated ‘living’ search which is followed by screening and extraction in a semi-automated fashion within a machine learning assisted graphical user interface. Relevant data is parsed and analyzed to compute mixed treatment comparisons and certainty of evidence is adjudicated using a rule-based algorithm. Detailed methods have been published before (PMID: 33824031). Results: As of October 1 st 2022, this LISR includes 16 clinical trials (30 references). Mixed treatment comparisons showed statistically significant PFS benefit with lenvatinib-pembrolizumab (LenPem; rank 1) when compared to cabozantinib-nivolumab (CabNivo; rank 3; hazard ratio [HR]: 0.69, 95% confidence interval: 0.52-0.93), CaboNivo-ipilimumab (CaboNivoIpi; rank 4; HR: 0.62; 0.43-0.89), avelumab-axitinib (AveAxi; rank 5; HR: 0.56; 0.43-0.75), PemAxi (rank 6; HR: 0.55; 0.42-0.72), atezolizumab-bevacizumab (AteBev; rank 7; HR: 0.46; 0.35-0.59), and NivoIpi (rank 8; HR: 0.45; 0.35-0.59). No significant differences were observed between CaboNivoIpi and other combination therapies for PFS improvement. Similarly, for OS, LenPem (rank 1), PemAxi (rank 2) and CaboNivo (rank 3) were ranked as potentially more efficacious treatment options than other counterparts. However, no statistically significant difference was observed for OS benefit with mixed treatment comparisons. The odds of achieving an ORR were higher with LenPem (rank 1; odds ratio [OR]: 2.44; 1.43-4.17), and CaboNivo (rank 2; OR: 1.77; 1.04-3.03) when compared to CaboNivoIpi (rank 6). NivoIpi (rank 1), LenPem (rank 2), CaboNivoIpi (rank 3) were ranked potentially as more efficacious treatments for achieving a CR. In terms of grade 3 or higher treatment related adverse events, NivoIpi (rank 3) was ranked as potentially the safest option among other combinations while CaboNivoIpi (rank 12), LenPem (rank 11), and CaboNivo (rank 10) were more likely to increase the risk of toxicity compared to most other treatments. Conclusions: Triplet combination of CaboNivoIpi may not provide additional survival benefit compared to other immunotherapy combinations and may increase toxicity. Patient-level considerations such as treatment toxicity, and quality of life should be factored in when opting intensified 1L therapies in mRCC patients." @default.
- W4324136885 created "2023-03-15" @default.
- W4324136885 creator A5013043483 @default.
- W4324136885 creator A5018306647 @default.
- W4324136885 creator A5030233600 @default.
- W4324136885 creator A5044173631 @default.
- W4324136885 creator A5047661479 @default.
- W4324136885 creator A5058350855 @default.
- W4324136885 creator A5058650905 @default.
- W4324136885 creator A5061593455 @default.
- W4324136885 creator A5063368856 @default.
- W4324136885 creator A5067550666 @default.
- W4324136885 creator A5068639858 @default.
- W4324136885 creator A5074582149 @default.
- W4324136885 date "2023-02-20" @default.
- W4324136885 modified "2023-09-26" @default.
- W4324136885 title "Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis." @default.
- W4324136885 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.695" @default.
- W4324136885 hasPublicationYear "2023" @default.
- W4324136885 type Work @default.
- W4324136885 citedByCount "0" @default.
- W4324136885 crossrefType "journal-article" @default.
- W4324136885 hasAuthorship W4324136885A5013043483 @default.
- W4324136885 hasAuthorship W4324136885A5018306647 @default.
- W4324136885 hasAuthorship W4324136885A5030233600 @default.
- W4324136885 hasAuthorship W4324136885A5044173631 @default.
- W4324136885 hasAuthorship W4324136885A5047661479 @default.
- W4324136885 hasAuthorship W4324136885A5058350855 @default.
- W4324136885 hasAuthorship W4324136885A5058650905 @default.
- W4324136885 hasAuthorship W4324136885A5061593455 @default.
- W4324136885 hasAuthorship W4324136885A5063368856 @default.
- W4324136885 hasAuthorship W4324136885A5067550666 @default.
- W4324136885 hasAuthorship W4324136885A5068639858 @default.
- W4324136885 hasAuthorship W4324136885A5074582149 @default.
- W4324136885 hasConcept C121608353 @default.
- W4324136885 hasConcept C126322002 @default.
- W4324136885 hasConcept C143998085 @default.
- W4324136885 hasConcept C207103383 @default.
- W4324136885 hasConcept C2775949291 @default.
- W4324136885 hasConcept C2776539811 @default.
- W4324136885 hasConcept C2777472916 @default.
- W4324136885 hasConcept C2777701055 @default.
- W4324136885 hasConcept C2779490328 @default.
- W4324136885 hasConcept C2780030458 @default.
- W4324136885 hasConcept C2780057760 @default.
- W4324136885 hasConcept C2781064419 @default.
- W4324136885 hasConcept C2781433595 @default.
- W4324136885 hasConcept C44249647 @default.
- W4324136885 hasConcept C71924100 @default.
- W4324136885 hasConceptScore W4324136885C121608353 @default.
- W4324136885 hasConceptScore W4324136885C126322002 @default.
- W4324136885 hasConceptScore W4324136885C143998085 @default.
- W4324136885 hasConceptScore W4324136885C207103383 @default.
- W4324136885 hasConceptScore W4324136885C2775949291 @default.
- W4324136885 hasConceptScore W4324136885C2776539811 @default.
- W4324136885 hasConceptScore W4324136885C2777472916 @default.
- W4324136885 hasConceptScore W4324136885C2777701055 @default.
- W4324136885 hasConceptScore W4324136885C2779490328 @default.
- W4324136885 hasConceptScore W4324136885C2780030458 @default.
- W4324136885 hasConceptScore W4324136885C2780057760 @default.
- W4324136885 hasConceptScore W4324136885C2781064419 @default.
- W4324136885 hasConceptScore W4324136885C2781433595 @default.
- W4324136885 hasConceptScore W4324136885C44249647 @default.
- W4324136885 hasConceptScore W4324136885C71924100 @default.
- W4324136885 hasIssue "6_suppl" @default.
- W4324136885 hasLocation W43241368851 @default.
- W4324136885 hasOpenAccess W4324136885 @default.
- W4324136885 hasPrimaryLocation W43241368851 @default.
- W4324136885 hasRelatedWork W2969242120 @default.
- W4324136885 hasRelatedWork W3119432592 @default.
- W4324136885 hasRelatedWork W3183205716 @default.
- W4324136885 hasRelatedWork W3194868076 @default.
- W4324136885 hasRelatedWork W3211505627 @default.
- W4324136885 hasRelatedWork W3216520672 @default.
- W4324136885 hasRelatedWork W4206901613 @default.
- W4324136885 hasRelatedWork W4221029189 @default.
- W4324136885 hasRelatedWork W4226292283 @default.
- W4324136885 hasRelatedWork W2995394561 @default.
- W4324136885 hasVolume "41" @default.
- W4324136885 isParatext "false" @default.
- W4324136885 isRetracted "false" @default.
- W4324136885 workType "article" @default.